Skip to content
DataLookout
Menu

NCT05270525

Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 6 more changesShow less
    • Eligibility criteria shortened, about 26 words
    • Final enrollment: 70 participants (planned 56)
    • Interventions modified
    • Secondary endpoints: 13 to 22
    • Study description shortened, about 274 words
    • Study title expanded, about 6 words
  2. Notable Eligibility criteria revised Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion pushed from Dec 2026 to Mar 1, 2027
    • Study completion moved earlier from Jun 2027 to Mar 1, 2027
    • Secondary endpoints: details revised at 1 of 13 entries
    • Study description expanded, about 7 words
    • Site details revised at 3 of 3 sites
  3. Notable Changed Sponsor changed: Verona Pharma plc to Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
  4. Notable Eligibility criteria expanded, about 9 wordsv6 Show 5 more changesShow less
    • Primary endpoint revised
    • Enrollment target: 50 to 56
    • Study sites: 2 to 3
    • Secondary endpoints: 7 to 13
    • Study description shortened, about 9 words
  5. Notable Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Dec 2024 to Jun 2027
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Site details revised at 1 of 2 sitesv4
  2. Notable Primary and study completion dates pushed to Dec 2024v3 Show 4 more changesShow less
    • Eligibility criteria revised
    • Enrollment target: 40 to 50
    • Study sites: 1 to 2
    • Study description shortened, about 32 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2022 to May 27, 2022
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers
Timeframe: Baseline and 8 Weeks

Secondary (22)

Absolute Change in Cell Numbers From Baseline in Sputum Cell Counts
Percent Change From Baseline in Sputum Cell Counts
Percent Change From Baseline in Cytokines
Percent Change From Baseline in Proteases
Percent Change From Baseline in Markers of Inflammation
Show 17 moreShow less
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 Weeks
Change From Baseline in FEV1 at 8 Weeks
Change From Baseline in Forced Vital Capacity (FVC) at 4 Weeks
Change From Baseline in FVC at 8 Weeks
Change From Baseline in Residual Volume (RV) at 4 Weeks
Change From Baseline in RV at 8 Weeks
Change From Baseline in Functional Residual Capacity (FRC) at 4 Weeks
Change From Baseline in FRC at 8 Weeks
Change From Baseline in Total Lung Capacity (TLC) at 4 Weeks
Change From Baseline in TLC at 8 Weeks
Number of Participants Who Experience One or More Adverse Events (AEs)
Change From Baseline in Systolic Blood Pressure
Change From Baseline in Diastolic Blood Pressure
Change From Baseline in Heart Rate
Change From Baseline in QRS Duration
Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
Change From Baseline in QT Interval

Arms and interventions

Ensifentrine Sequence 1Experimental

In treatment period 1 participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 1 participants will receive LABA/LAMA background therapy.

Ensifentrine Sequence 2Experimental

In treatment period 1 participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 2 participants will receive LABA/LAMA background therapy.

Drugs: Ensifentrine, Placebo, LABA/LAMA

Sites

3 sites in 1 country